advertisement
Harris A 12
Showing records 1 to 12 | Display all abstracts from Harris A95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Torabi R
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Stoner A; Harris A
British Journal of Ophthalmology 2022; 106: 1332-1337
95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Harris A
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Oddone F
British Journal of Ophthalmology 2022; 106: 1332-1337
95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Siesky B
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Belamkar A
British Journal of Ophthalmology 2022; 106: 1332-1337
95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Zukerman R; Oddone F
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Verticchio Vercellin AC
British Journal of Ophthalmology 2022; 106: 1332-1337
95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Mathew S
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Shin J; Januleviciene I
British Journal of Ophthalmology 2022; 106: 1332-1337
95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Januleviciene I; Vercellin ACV
Journal of ophthalmic & vision research 2021; 16: 644-656
95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Siesky B
British Journal of Ophthalmology 2022; 106: 1332-1337
